Literature DB >> 21565252

A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity.

Matthew A Schreiber1, Steven L McIntire.   

Abstract

Biogenic amine systems are damaged by amphetamine abuse and in Parkinson's disease. The mechanisms mediating this damage are of high importance because of the public health impact of these problems. Here we have taken advantage of the Caenorhabditis elegans nematode model system to investigate genetic modifiers of biogenic amine toxicity. In a forward genetic screen, we identified a mutant resistant to the toxic effects of dopamine. This mutant was also resistant to toxic doses of methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA). In addition, this mutation conferred resistance to 6-hydroxydopamine damage to dopaminergic neurons in a Parkinson's disease model. Resistance was due to a mutation in the nsy-1 gene, orthologous to the mammalian ASK-1 MAPKKK. NSY-1 is in the highly conserved p38 MAP kinase pathway, which plays a crucial role in C. elegans innate immunity, suggesting that this pathway may play a role in biogenic amine toxicity system damage due to amphetamines and in the pathogenesis of Parkinson's disease in higher organisms.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565252      PMCID: PMC3119726          DOI: 10.1016/j.neulet.2011.04.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  37 in total

1.  Lateral signaling mediated by axon contact and calcium entry regulates asymmetric odorant receptor expression in C. elegans.

Authors:  E R Troemel; A Sagasti; C I Bargmann
Journal:  Cell       Date:  1999-11-12       Impact factor: 41.582

2.  Parkinson's disease-associated DJ-1 modulates innate immunity signaling in Caenorhabditis elegans.

Authors:  Elena M Cornejo Castro; Jens Waak; Stephanie S Weber; Fabienne C Fiesel; Philipp Oberhettinger; Monika Schütz; Ingo B Autenrieth; Wolfdieter Springer; Philipp J Kahle
Journal:  J Neural Transm (Vienna)       Date:  2010-04-08       Impact factor: 3.575

3.  Genetic analysis of Caenorhabditis elegans innate immunity.

Authors:  Michael Shapira; Man-Wah Tan
Journal:  Methods Mol Biol       Date:  2008

4.  A genetic survey of fluoxetine action on synaptic transmission in Caenorhabditis elegans.

Authors:  Andrey Kullyev; Catherine M Dempsey; Sarah Miller; Chih-Jen Kuan; Vera M Hapiak; Richard W Komuniecki; Christine T Griffin; Ji Ying Sze
Journal:  Genetics       Date:  2010-08-25       Impact factor: 4.562

5.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis.

Authors:  K Tobiume; A Matsuzawa; T Takahashi; H Nishitoh; K Morita ; K Takeda; O Minowa; K Miyazono; T Noda; H Ichijo
Journal:  EMBO Rep       Date:  2001-03       Impact factor: 8.807

6.  Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine.

Authors:  R Ranganathan; E R Sawin; C Trent; H R Horvitz
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

7.  C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway.

Authors:  E R Sawin; R Ranganathan; H R Horvitz
Journal:  Neuron       Date:  2000-06       Impact factor: 17.173

8.  The CaMKII UNC-43 activates the MAPKKK NSY-1 to execute a lateral signaling decision required for asymmetric olfactory neuron fates.

Authors:  A Sagasti; N Hisamoto; J Hyodo; M Tanaka-Hino; K Matsumoto; C I Bargmann
Journal:  Cell       Date:  2001-04-20       Impact factor: 41.582

9.  Isolation and characterization of pmk-(1-3): three p38 homologs in Caenorhabditis elegans.

Authors:  K Berman; J McKay; L Avery; M Cobb
Journal:  Mol Cell Biol Res Commun       Date:  2001-11

10.  C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging.

Authors:  Tjakko J van Ham; Karen L Thijssen; Rainer Breitling; Robert M W Hofstra; Ronald H A Plasterk; Ellen A A Nollen
Journal:  PLoS Genet       Date:  2008-03-21       Impact factor: 5.917

View more
  5 in total

1.  Embryonic Methamphetamine Exposure Inhibits Methamphetamine Cue Conditioning and Reduces Dopamine Concentrations in Adult N2 Caenorhabditis elegans.

Authors:  Simon N Katner; Bethany S Neal-Beliveau; Eric A Engleman
Journal:  Dev Neurosci       Date:  2016-05-28       Impact factor: 2.984

Review 2.  Caenorhabditis elegans as a Model to Study the Molecular and Genetic Mechanisms of Drug Addiction.

Authors:  Eric A Engleman; Simon N Katner; Bethany S Neal-Beliveau
Journal:  Prog Mol Biol Transl Sci       Date:  2015-11-24       Impact factor: 3.622

3.  n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.

Authors:  Ru-Huei Fu; Horng-Jyh Harn; Shih-Ping Liu; Chang-Shi Chen; Wen-Lin Chang; Yue-Mi Chen; Jing-En Huang; Rong-Jhu Li; Sung-Yu Tsai; Huey-Shan Hung; Woei-Cherng Shyu; Shinn-Zong Lin; Yu-Chi Wang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

4.  Dopamine-dependent, swimming-induced paralysis arises as a consequence of loss of function mutations in the RUNX transcription factor RNT-1.

Authors:  Sarah B Robinson; Osama Refai; J Andrew Hardaway; Sarah Sturgeon; Tessa Popay; Daniel P Bermingham; Phyllis Freeman; Jane Wright; Randy D Blakely
Journal:  PLoS One       Date:  2019-05-13       Impact factor: 3.240

Review 5.  p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease.

Authors:  Saurabh Kumar Jha; Niraj Kumar Jha; Rohan Kar; Rashmi K Ambasta; Pravir Kumar
Journal:  Int J Mol Cell Med       Date:  2015
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.